Merendino Lauren 4

What Happened

• Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals (DAWN), received two equity awards on January 30, 2026: a 110,000‑share derivative award (option) and a 74,000‑share derivative award (RSUs). Both were granted at $0.00 per share (i.e., equity compensation awards rather than purchases), so there was no cash paid by the reporting person at grant. These are time‑based awards that convert into common shares only if and when vesting conditions are met.

Key Details

• Transaction date: 2026-01-30 (filed accession 0001855298-26-000002).
• Awards: 110,000 derivative units (option—vests monthly) and 74,000 derivative units (RSUs—contingent rights to shares).
• Grant price: $0.00 per share (standard for awards); immediate cash value listed as $0 in the filing (future value depends on DAWN’s stock price at settlement).
• Vesting:
  • Option (110,000): vests 1/48th monthly beginning Feb 28, 2026, subject to continued service. (Footnote F1)
  • RSUs (74,000): each RSU converts to one share on settlement; vests 1/16th quarterly on Feb 15, May 15, Aug 15 and Nov 15, subject to continued service. RSUs do not expire. (Footnotes F2–F4)
• Shares owned after the reported transaction: not disclosed in the Form 4 filing.
• Filing timeliness: filing shows the grant on 2026-01-30 and was submitted with this report; no late‑filing indication noted in the supplied data.
• No evidence in this filing of immediate sale, cashless exercise, tax withholding, or a 10b5-1 plan.

Context

• These are compensation grants, not open‑market purchases or sales. Such awards are routine for executives and are primarily tied to continued service and company performance; they do not represent an immediate transfer of freely tradable shares until vesting/settlement occurs.